“Support of 60 to 80%” for a non-mandatory vaccination campaign “is unheard of,” Audrey Derveloy, president of Sanofi France, said this Wednesday about the new treatment against bronchiolitis in newborns.
“It is a true therapeutic innovation,” emphasizes the leader, who is happy that the State has launched a vaccination campaign so quickly “in record time, it is something unheard of.” Furthermore, the first baby in the world to have access to this treatment was French.
The problem is that this parental support for Beyfortus (developed by Sanofi and AstraZeneca) very quickly caused stock shortages in the pharmacies where it is distributed.
Bring treatment as close as possible to those who need it
For Audrey Derveloy, this is above all a priority problem.
In fact, health authorities announced last week that they would stop pharmacy deliveries of this monoclonal antibody and reserved the lowest dose (50 mg) for newborns in maternity hospitals before their discharge, and for infants less than one year old. month hospitalized.
“It is these little babies who need it and I think common sense is to bring these doses as close as possible to those who need them,” the leader repeats.
Source: BFM TV
